This disclosure concerns expandable devices, specifically self-deployed devices, for adherence to a tissue, for example intestinal tissue. The disclosure also concerns expandable devices, specifically self-deployed devices for delivery of at least one active agent to, or across, a tissue.

An example system includes a fluid delivery device configured to deliver gas nanobubbles to a target site of a patient from a solution comprising a fluid, supersaturated with a. gas, wherein the fluid delivery' device defines a flow channel configured to flow the solution through the flow channel such that the gas in the supersaturated fluid forms gas nanobubbles as the solution flows through the flow channel towards the target site, and wherein the gas nanobubbles remain in the fluid at least until delivery' to the target site.

A swallowable oral drug delivery device comprises: a driving part including an actuator, and a cylinder linearly moving by means of the actuator; a drug accommodation part including a first chamber for accommodating a piston linked with the cylinder to linearly move and an inactivated first drug, a second chamber for accommodating a second drug activating the first drug, a separation membrane for isolating the first chamber from the second chamber, and an outlet membrane for closing an outlet allowing either the first chamber or the second chamber to communicate with an external environment; a sensing part for identifying the movement or position of the drug delivery device; and a control part for receiving a signal provided from the sensing part, and controlling the operation of the actuator on the basis of the signal.

A catheter including an outer tube; a first inner tube disposed within the outer tube; a second inner tube disposed within the outer tube and parallel to the first inner tube, and having an insertion opening at its proximal end and a distal end opening at its distal end; and a first core wire and a second core wire disposed between the first inner tube and an outer tube. The second inner tube extends from a medial region of the catheter to a distal end of the catheter. A distal end of the first core wire is located distal to the insertion opening of the second inner tube, and a distal end of the second core wire is located proximal to the insertion opening of the second inner tube. The second core wire can move between the outer tube and the first inner tube.

In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

The invention provides systems and components thereof for ultrasound-mediated drug delivery within the GI tract delivery of therapeutic agents to the gastrointestinal tract of a subject. The systems comprise a transmitter that includes a power source and power emitter for transmitting EM and non-EM energy. The power transmitter comprises one or more capacitive, inductive, magnetic resonance. RF, or ultrasonic energy radiator. The second component is an ingestible capsule that is physically separate from the transmitter. The ingestible capsule may be configured to harvest energy from the transmitter using a variety of components. In various embodiments, the ingestible pill comprises at least one energy harvesting component, an ultrasound transducer, and a reservoir or payload that releasably retains a liquid or powder mixture containing an encapsulated or non-encapsulated therapeutic agent. When in use, the ingestible capsule enters the GI tract of the subject, while the transmitter remains external to the subject's body.

A fluid delivery device and system configured to regulate delivery of fluid through a fluid delivery port to a target site within a patient, such as to identify, locate, dilate, etc., an opening in a tissue wall at the target site. A side port is defined in the wall of the fluid delivery device adjacent to but upstream of the fluid delivery port. If the fluid delivery port is partially or fully obstructed by contacting tissue, the side port provides a relief valve reducing the pressure of fluid from the fluid delivery port impacting the contacted tissue. The fluid flow path upstream of and adjacent to the side port may be tapered to create a Venturi effect which may cause entrainment of excess fluid at the target site into the fluid delivery device. Such entrained fluid may be recycled out the fluid delivery port.

A gastric tube for use in a bariatric surgical procedure includes an elongate tube and an anchor. The elongate tube has a proximal end portion and a distal end portion and defines a lumen along a length thereof. The proximal end portion defines an opening in communication with the lumen. The elongate tube includes a blunt tip, a light source, and an outer surface. The blunt tip is formed on the distal end portion and is at least partially transparent. The light source is in communication with the blunt tip for illuminating at least the blunt tip. The outer surface extends between the proximal and distal end portions and defines a side opening in communication with the lumen.